Catalyst overview
Research summary
This catalyst tracks a Phase 2/3 data readout for BHV-7000 in Focal Epilepsy. The expected timing is based on the latest available company guidance and may change.
12/6/24- Present MAD data via poster at AES 2024 Annual Meeting on December 6-10, 2024. 5/12/25- Topline results in H1 2026. 11/10/25:- Kv7 activator opakalim in two Phase 2/3 focal epilepsy studies; initial topline results expected in H1 2026. 01/12/26:- OLE data show ≥50% responder rate; opakalim well tolerated. Pivotal topline results now expected in 2026. 03/02/26:- OLE opakalim showed ≥50% seizure reduction for most; pivotal topline focal epilepsy data expected H2 2026. 05/04/26:- Two Ph2/3 focal epilepsy studies ongoing; initial topline for first study expected in 2H 2026. 05/26/26:- Added IGE and OLE data; pivotal Ph2/3 NCT06132893 topline still expected H2 2026. 06/30/26:- RISE3 enrollment complete. Topline focal epilepsy results expected in H2 2026. 08/10/26:- OLE data showed durable seizure reduction; RISE3 topline remains expected in 2H 2026.
Verification
Confirm timing and program details against the company announcement or filing.